FDA Division Director to NCI

Edward Tabor, MD, director of Anti-Infective Drug Products Division, selected as associate director of the National Cancer Institute's biological carcinogenesis program. Tabor will be responsible for all intramural and extramural programs dealing with viral causes of cancer and have a budget of $100 mil. Office of Drug Review II Director James Bilstad, MD, has not yet appointed an acting director for the anti-infective drug division. Tabor will replace Acting Associate Director Richard Adamson, RhD, who is Director of NCI's Division of Cancer Etiology.